A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review).
Cutaneous squamous cell carcinoma
Epithelial-mesenchymal transition
Metastasis
Systematic review
Targeted therapy
UV-induced
Urokinase plasminogen activator system
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
28
04
2022
accepted:
27
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) is a disease with globally rising incidence and poor prognosis for patients with advanced or metastatic disease. Epithelial-mesenchymal transition (EMT) is a driver of metastasis in many carcinomas, and cSCC is no exception. We aimed to provide a systematic overview of the clinical and experimental evidence for EMT in cSCC, with critical appraisal of type and quality of the methodology used. We then used this information as rationale for potential drug targets against advanced and metastatic cSCC. All primary literature encompassing clinical and cell-based or xenograft experimental studies reporting on the role of EMT markers or related signalling pathways in the progression of cSCC were considered. A screen of 3443 search results yielded 86 eligible studies comprising 44 experimental studies, 22 clinical studies, and 20 studies integrating both. From the clinical studies a timeline illustrating the alteration of EMT markers and related signalling was evident based on clinical progression of the disease. The experimental studies reveal connections of EMT with a multitude of factors such as genetic disorders, cancer-associated fibroblasts, and matrix remodelling via matrix metalloproteinases and urokinase plasminogen activator. Additionally, EMT was found to be closely tied to environmental factors as well as to stemness in cSCC via NFκB and β-catenin. We conclude that the canonical EGFR, canonical TGF-βR, PI3K/AKT and NFκB signalling are the four signalling pillars that induce EMT in cSCC and could be valuable therapeutic targets. Despite the complexity, EMT markers and pathways are desirable biomarkers and drug targets for the treatment of advanced or metastatic cSCC.
Identifiants
pubmed: 35666359
doi: 10.1007/s12672-022-00510-4
pii: 10.1007/s12672-022-00510-4
pmc: PMC9170863
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
42Subventions
Organisme : National Health and Medical Research Council
ID : APP1181179
Informations de copyright
© 2022. The Author(s).
Références
J Dermatol Sci. 2010 Nov;60(2):105-13
pubmed: 20851575
Arch Dermatol Res. 2013 Jan;305(1):35-47
pubmed: 22740085
J Dermatol Sci. 2010 May;58(2):97-104
pubmed: 20399617
Biochem Biophys Res Commun. 2013 Jan 18;430(3):1078-82
pubmed: 23261444
J Cell Sci. 2009 Jun 1;122(Pt 11):1788-99
pubmed: 19435799
Nat Rev Cancer. 2008 Jul;8(7):535-45
pubmed: 18548086
Arch Dermatol Res. 2015 Oct;307(8):721-9
pubmed: 26094020
Oncotarget. 2015 Aug 21;6(24):20525-39
pubmed: 25971211
Nat Cell Biol. 2015 May;17(5):678-88
pubmed: 25893917
Curr Oncol. 2020 Aug;27(4):e399-e407
pubmed: 32905333
Adv Exp Med Biol. 2008;637:19-27
pubmed: 19181107
Cancer Res. 2009 May 1;69(9):4081-91
pubmed: 19383899
J Am Acad Dermatol. 2022 Feb;86(2):331-338
pubmed: 34653569
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12
pubmed: 20440544
BMC Oral Health. 2021 Nov 23;21(1):598
pubmed: 34814915
J Invest Dermatol. 2019 Jul;139(7):1449-1458.e1
pubmed: 30684551
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
pubmed: 31886121
J Clin Med. 2020 Feb 25;9(3):
pubmed: 32106476
Biochem J. 2007 Dec 1;408(2):203-10
pubmed: 17696882
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331425
J Biomed Biotechnol. 2011;2011:567305
pubmed: 22007144
J Dermatol Sci. 2021 Jun;102(3):184-192
pubmed: 34016486
Onco Targets Ther. 2020 Oct 09;13:10097-10109
pubmed: 33116592
J Natl Cancer Inst. 2015 Oct 16;108(1):
pubmed: 26476432
Breast Cancer Res. 2020 Jul 8;22(1):74
pubmed: 32641077
Int J Mol Sci. 2018 May 08;19(5):
pubmed: 29738493
Br J Dermatol. 2020 Apr;182(4):995-1002
pubmed: 31299087
Oncotarget. 2017 Sep 18;8(63):107334-107345
pubmed: 29291033
Cancer Cell Int. 2003 Oct 14;3(1):17
pubmed: 14613514
Folia Histochem Cytobiol. 2018;56(4):195-206
pubmed: 30569446
Thyroid Res. 2012 Jan 26;5(1):1
pubmed: 22280879
Cancers (Basel). 2021 Aug 14;13(16):
pubmed: 34439251
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):266-74
pubmed: 26837418
Lung Cancer. 2020 Jan;139:1-8
pubmed: 31683225
Nat Commun. 2019 Dec 6;10(1):5587
pubmed: 31811131
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Toxicol Appl Pharmacol. 2017 Sep 15;331:130-134
pubmed: 28595984
Oncogene. 2017 Mar 30;36(13):1779-1792
pubmed: 27641329
Orphanet J Rare Dis. 2016 Aug 20;11(1):117
pubmed: 27544590
Toxicol Lett. 2015 Sep 17;237(3):191-9
pubmed: 26101800
JAMA Dermatol. 2019 Mar 1;155(3):298-306
pubmed: 30484823
Oncogene. 2014 Aug 7;33(32):4185-92
pubmed: 24056961
Cancer Sci. 2011 Oct;102(10):1829-39
pubmed: 21752154
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:6-10
pubmed: 31833607
J Cell Sci. 2019 Jan 9;132(1):
pubmed: 30559248
Pathol Oncol Res. 2014 Apr;20(2):263-6
pubmed: 23999979
Cancer Res. 2011 Aug 1;71(15):5317-26
pubmed: 21685475
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Virchows Arch. 2012 May;460(5):481-7
pubmed: 22460857
Oncol Rep. 2019 Nov;42(5):1805-1814
pubmed: 31545452
Biochem Biophys Res Commun. 2019 Sep 3;516(4):1110-1115
pubmed: 31284949
BMC Complement Altern Med. 2011 Dec 21;11:134
pubmed: 22188922
Front Oncol. 2021 Apr 13;11:646399
pubmed: 33928036
Oncotarget. 2015 Dec 8;6(39):41497-507
pubmed: 26594799
J Am Acad Dermatol. 2018 Feb;78(2):237-247
pubmed: 29332704
Virchows Arch. 2008 Sep;453(3):267-74
pubmed: 18712413
J Biol Chem. 2011 Nov 4;286(44):38757-38767
pubmed: 21880709
Biomed Res Int. 2019 Nov 22;2019:2076579
pubmed: 31886179
J Invest Dermatol. 2018 Sep;138(9):2063-2066
pubmed: 29601811
Curr Opin Chem Biol. 2018 Jun;44:75-86
pubmed: 29908451
Methods Mol Biol. 2018;1706:293-302
pubmed: 29423805
NPJ Precis Oncol. 2021 Jun 22;5(1):56
pubmed: 34158591
PLoS One. 2013 Nov 08;8(11):e80076
pubmed: 24260338
Hum Pathol. 2011 Apr;42(4):482-8
pubmed: 21237487
Dev Cell. 2014 Apr 14;29(1):1-2
pubmed: 24735874
J Dermatolog Treat. 2022 Feb;33(1):373-379
pubmed: 32338086
Front Oncol. 2022 Apr 11;12:835929
pubmed: 35480116
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
JAMA Dermatol. 2017 Aug 1;153(8):781-788
pubmed: 28678985
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
Virchows Arch. 2015 Mar;466(3):357-8
pubmed: 25420898
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):39-50
pubmed: 34592000
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
Cells. 2020 Apr 30;9(5):
pubmed: 32365809
Br J Cancer. 2018 Apr;118(8):1089-1097
pubmed: 29551776
Clin Cancer Res. 2021 Jun 1;27(11):3215-3223
pubmed: 33795258
Cancer Cell Int. 2019 Oct 21;19:270
pubmed: 31649487
Cancers (Basel). 2020 Mar 18;12(3):
pubmed: 32197405
Biomedicines. 2021 Feb 09;9(2):
pubmed: 33572373
Exp Dermatol. 2021 May;30(5):664-675
pubmed: 33595864
Trends Biochem Sci. 2010 Mar;35(3):161-8
pubmed: 19884009
Onco Targets Ther. 2019 Nov 07;12:9395-9405
pubmed: 31807020
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Sci Rep. 2020 Feb 27;10(1):3652
pubmed: 32107458
Front Genet. 2021 Jun 24;12:661306
pubmed: 34249086
Cancer Biol Ther. 2020 Sep 1;21(9):815-825
pubmed: 32723205
J Cancer. 2017 Jan 15;8(2):220-226
pubmed: 28243326
J Korean Med Sci. 2018 Dec 26;34(1):e5
pubmed: 30618513
Virchows Arch. 2009 May;454(5):549-55
pubmed: 19381684
Oncotarget. 2016 Aug 30;7(35):57351-57366
pubmed: 27385000
Anticancer Res. 2020 Jun;40(6):3559-3564
pubmed: 32487658
Dermatology. 2016;232(5):558-565
pubmed: 27875814
Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2
pubmed: 26083672
Eur J Dermatol. 2013 May-Jun;23(3):413-4
pubmed: 23783178
Mod Pathol. 2017 Jul;30(7):919-927
pubmed: 28339425
Exp Ther Med. 2020 Feb;19(2):1065-1071
pubmed: 32010270
Eur J Pharmacol. 2018 Apr 15;825:133-142
pubmed: 29476880
J Clin Invest. 2008 Aug;118(8):2722-32
pubmed: 18618014
Adv Wound Care (New Rochelle). 2014 Mar 1;3(3):281-290
pubmed: 24669362
J Invest Dermatol. 2019 Aug;139(8):1658-1671.e8
pubmed: 30710576
Cell Death Dis. 2013 Oct 10;4:e848
pubmed: 24113182
Am J Pathol. 2012 Apr;180(4):1581-92
pubmed: 22326752
Exp Ther Med. 2021 Feb;21(2):116
pubmed: 33335579
An Bras Dermatol. 2019 Nov - Dec;94(6):637-657
pubmed: 31789244
J Psychiatry Neurosci. 2012 May;37(3):149-52
pubmed: 22515987
Curr Opin Cell Biol. 2004 Oct;16(5):558-64
pubmed: 15363807
Virchows Arch. 2014 Sep;465(3):339-50
pubmed: 25031014
Dev Dyn. 2018 Mar;247(3):368-381
pubmed: 28758355
Acta Derm Venereol. 2020 Sep 23;100(16):adv00266
pubmed: 32930344
Cancer Metastasis Rev. 2019 Sep;38(3):483-492
pubmed: 31734763
Biochem Biophys Res Commun. 2012 Aug 24;425(2):177-81
pubmed: 22820192
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
J Invest Dermatol. 2019 Feb;139(2):369-379
pubmed: 30248333
Cancer Sci. 2011 Apr;102(4):815-27
pubmed: 21219539
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9241-6
pubmed: 24927592
Arch Toxicol. 2021 Jul;95(7):2351-2365
pubmed: 34032870
J Eur Acad Dermatol Venereol. 2015 May;29(5):991-7
pubmed: 25428612
Ann Plast Surg. 2015 Sep;75(3):323-6
pubmed: 24401812
Oncol Rep. 2018 Nov;40(5):2558-2572
pubmed: 30132555
Oncoimmunology. 2017 Apr 20;6(12):e1315488
pubmed: 29209560
Front Oncol. 2019 Jul 25;9:669
pubmed: 31404273
Oncotarget. 2017 Jun 27;8(26):43228-43236
pubmed: 28591732
Oncol Rep. 2021 Apr;45(4):
pubmed: 33649811
Semin Cell Dev Biol. 2010 Oct;21(8):855-63
pubmed: 20837152
Am J Epidemiol. 2001 Mar 15;153(6):559-65
pubmed: 11257063
J Dermatol Sci. 2013 Nov;72(2):93-102
pubmed: 23928229
J Cell Biochem. 2018 Dec;119(12):10393-10405
pubmed: 30145798
Hum Pathol. 2018 Sep;79:1-8
pubmed: 29555579
Oncogene. 2018 Jan 11;37(2):218-230
pubmed: 28925390
Dermatol Clin. 2010 Jan;28(1):115-8
pubmed: 19945623
J Med Chem. 2018 Sep 27;61(18):8299-8320
pubmed: 30130401
PLoS One. 2013;8(3):e58915
pubmed: 23516577
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Eur Acad Dermatol Venereol. 2018 Apr;32(4):581-586
pubmed: 28796927
J Cell Biochem. 2005 Aug 1;95(5):918-31
pubmed: 15861394
Arch Toxicol. 2013 Jun;87(6):991-1000
pubmed: 23069812
Toxicol Res (Camb). 2016 May 9;5(4):1140-1147
pubmed: 30090420
Nat Commun. 2019 Nov 27;10(1):5410
pubmed: 31776338
Trends Cancer. 2020 May;6(5):432-441
pubmed: 32348738
J Eur Acad Dermatol Venereol. 2009 Feb;23(2):214-5
pubmed: 18482319
Australas J Dermatol. 2022 May;63(2):213-216
pubmed: 35397123
Cancer Res. 2011 Apr 15;71(8):2959-68
pubmed: 21385899
J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1365-6
pubmed: 20384675
J Cancer. 2019 Aug 27;10(20):4883-4891
pubmed: 31598160
Oncogene. 2021 Sep;40(39):5799-5813
pubmed: 34345013
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739489
Int J Mol Sci. 2020 Dec 06;21(23):
pubmed: 33291277
Br J Dermatol. 2014 Nov;171(5):1014-21
pubmed: 24628329
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
J Cell Physiol. 2019 Dec;234(12):22207-22219
pubmed: 31192452
J Cutan Pathol. 2013 Jul;40(7):651-6
pubmed: 23521708
Cancer Sci. 2018 Nov;109(11):3643-3656
pubmed: 30194792
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S20-S25
pubmed: 27611935
Mol Carcinog. 2011 Jul;50(7):516-27
pubmed: 21308804
Arch Dermatol Res. 2022 Oct;314(8):767-775
pubmed: 34647185
J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:5-7
pubmed: 28263020
Rev Environ Health. 2014;29(3):255-64
pubmed: 25222586
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1164-75
pubmed: 24793954
Skin Health Dis. 2021 Apr 01;1(2):e27
pubmed: 35664979
J Biol Chem. 2006 Apr 14;281(15):10206-13
pubmed: 16459332
PLoS One. 2013 May 10;8(5):e63607
pubmed: 23675494
J Am Acad Dermatol. 2018 Mar;78(3):560-578
pubmed: 29331386
Cancers (Basel). 2021 Mar 08;13(5):
pubmed: 33800195
Biomolecules. 2022 Jan 18;12(2):
pubmed: 35204653
J Dermatol. 2018 Jun;45(6):748-750
pubmed: 29864224
Oncogene. 2016 Aug 25;35(34):4529-39
pubmed: 26804167
Hum Pathol. 2008 Mar;39(3):344-9
pubmed: 18045646
Matrix Biol. 2015 Sep;47:54-65
pubmed: 25960420
Exp Dermatol. 2000 Apr;9(2):104-17
pubmed: 10772384
Adv Exp Med Biol. 2017;996:15-23
pubmed: 29124687
BMC Cancer. 2013 Mar 21;13:137
pubmed: 23514407
Head Neck. 2017 Jul;39(7):1462-1469
pubmed: 28370784
Exp Mol Pathol. 2016 Jun;100(3):378-85
pubmed: 27019369
Am J Transl Res. 2021 Aug 15;13(8):9233-9240
pubmed: 34540039
Int J Mol Sci. 2019 Jul 12;20(14):
pubmed: 31336867
Drugs. 2020 Jun;80(8):813-819
pubmed: 32306208
Bioorg Med Chem Lett. 2019 Dec 15;29(24):126753
pubmed: 31679971
Clin Exp Metastasis. 2016 Jan;33(1):53-62
pubmed: 26507436
Cell Rep. 2019 Aug 27;28(9):2358-2372.e6
pubmed: 31461652